We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: Tirzepatide yields sustained weight discount in weight problems and prediabetes, finds research
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > Tirzepatide yields sustained weight discount in weight problems and prediabetes, finds research
Tirzepatide yields sustained weight discount in weight problems and prediabetes, finds research
Health

Tirzepatide yields sustained weight discount in weight problems and prediabetes, finds research

Last updated: November 19, 2024 7:02 am
Editorial Board Published November 19, 2024
Share
SHARE

For sufferers with weight problems and prediabetes, three years of tirzepatide yields substantial and sustained weight discount and a lowered threat for development to sort 2 diabetes, in keeping with a research revealed within the New England Journal of Medication.

Ania M. Jastreboff, M.D., Ph.D., from the Yale College of Medication in New Haven, Connecticut, and colleagues carried out a part 3, double-blind trial involving 2,539 individuals with weight problems (1,032 of whom additionally had prediabetes), who have been randomly assigned to obtain tirzepatide at a once-weekly dose of 5, 10, or 15 mg or placebo in a 1:1:1:1 ratio. The present evaluation included the individuals with weight problems and prediabetes who acquired tirzepatide or placebo for 176 weeks adopted by an off-treatment interval of 17 weeks.

The researchers discovered that the imply share change in physique weight at 176 weeks was −12.3, −18.7, and −19.7% for these receiving 5-, 10-, and 15-mg tirzepatide doses, respectively, in contrast with −1.3% for these receiving placebo.

Receipt of a analysis of sort 2 diabetes occurred in fewer individuals within the tirzepatide teams versus the placebo group (1.3 versus 13.3%; hazard ratio, 0.07). After 17 weeks off therapy, 2.4 and 13.7% of those that acquired tirzepatide and placebo, respectively, had sort 2 diabetes (hazard ratio, 0.12). Other than COVID-19, the most typical adversarial occasions have been gastrointestinal, most of which have been mild-to-moderate in severity.

“Tirzepatide therapy resulted in sustained weight reduction that was accompanied by a markedly lower risk of progression to type 2 diabetes than that with placebo,” the authors write.

Extra data:
Ania M. Jastreboff et al, Tirzepatide for Weight problems Therapy and Diabetes Prevention, New England Journal of Medication (2024). DOI: 10.1056/NEJMoa2410819

2024 HealthDay. All rights reserved.

Quotation:
Tirzepatide yields sustained weight discount in weight problems and prediabetes, finds research (2024, November 18)
retrieved 19 November 2024
from https://medicalxpress.com/information/2024-11-tirzepatide-yields-sustained-weight-reduction.html

This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.

You Might Also Like

Key mind protein might maintain solutions for reminiscence loss and neurodegenerative ailments

Early-onset neonatal sepsis linked to childhood epilepsy

Energy in numbers: Examine finds small group teaching reduces charges of doctor burnout by almost 30%

RFK Jr. cancels key US well being panel assembly with out warning, elevating issues

Examine exhibits how brain-to-computer ‘electroceuticals’ will help restore cognition

TAGGED:findsObesityPrediabetesreductionstudysustainedTirzepatideWeightyields
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
Commanders’ possession change stacks NFC East management panorama in opposition to Giants
Sports

Commanders’ possession change stacks NFC East management panorama in opposition to Giants

Editorial Board January 28, 2025
Standardized screening finds extra younger kids more likely to have autism
Jets mailbag: Ought to NY discover buying and selling up for Miami’s Cam Ward?
F.C.C. revokes the ability of China Unicom to operate in the U.S.
Dan Fogelman’s clues to ‘Paradise’ Season 2: Jane’s backstory, the surface world and extra

You Might Also Like

Merely ‘sprinkling’ a fluorescent probe can shortly present lively mind synapses
Health

Merely ‘sprinkling’ a fluorescent probe can shortly present lively mind synapses

July 11, 2025
Mathematical mannequin reveals how people retailer narrative recollections utilizing ‘random timber’
Health

Mathematical mannequin reveals how people retailer narrative recollections utilizing ‘random timber’

July 11, 2025
Olorofim Part IIb trial exhibits efficacy in invasive fungal illness for sufferers with restricted remedy choices
Health

Olorofim Part IIb trial exhibits efficacy in invasive fungal illness for sufferers with restricted remedy choices

July 11, 2025
Premenstrual signs linked to elevated danger of heart problems
Health

Premenstrual signs linked to elevated danger of heart problems

July 11, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?